Laurus Labs informs about company updates

05 Sep 2019

Laurus Labs has informed that it has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (US FDA) for its API Units 1& 3, located at Parawada, Visakhapatnam, for the inspection conducted in June 2019. And in FDF segment Laurus Labs received Global Fund (GF) ERP (Expert Review Panel) approval for FDC (Fixed Dose Combination) TLE 400 (Tenofovir/Lamivudine/Efavirenz 300/300/400mg) for supply in GF funded projects. Laurus Labs is one among the three companies to receive the approval for this product in ART (Anti Retro Viral Therapy). A press release to this extent is enclosed.

The above information is a part of company’s filings submitted to BSE.

Related Laurus Labs Ltd. Links:

Laurus Labs Share Price

571.50 -0.30 (-0.05%) Jul 10, 11:39
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 494.75
Dr. Reddys Lab 3929.60
Lupin 870.60
Piramal Enterprises 1457.00
Cadila Healthcare 357.90
View more..
Sensex vs Laurus Labs
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback